Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC)
and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene …

Background Most patients with non–small-cell lung cancer have no response to the tyrosine
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR) …

Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for
regulating tumorigenesis and cell survival and may be important in the development and …

The successes achieved by chimeric antigen receptor-modified T (CAR-T) cells in
hematological malignancies raised the possibility of their use in non-small lung cancer …

Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and
antifolate drugs. Cancer drug development since then has transformed from a low-budget …

Functional activation of growth factors and receptors of the epidermal growth factor receptor
(EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer …

Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor
receptor (EGFR), has the potential to increase survival in patients with advanced non-small …

Resistance to chemotherapy limits the effectiveness of anti‐cancer drug treatment. Tumours
may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment …

Next-generation sequencing technologies have greatly expanded our understanding of
cancer genetics. Antisense technology is an attractive platform with the potential to translate …